Presentation Type: Speech
Over the past 5 decades, cardiovascular medicine has advanced through the melding of diverse scientific and technical concepts. Strategies for prediction, prevention, intervention, molecular genetics, and regeneration have been tested for clinical relevance and applicability by various risk profiling and clinical trial techniques. One of the more recent of these strategic concepts is regenerative therapy, which targets repair or replacement of lost or dysfunctional substrates. Regenerative strategies have moved rapidly to clinical application for subsets of patients, including those with heart disease, and during the past 2 decades, thousands of patients have been administered various types of stem cells in clinical cardiac disease studies ranging from proof-of-concept to phase 2 trials. These clinical cardiac applications have focused in part on patients for whom preventive and conventional intervention strategies failed to avert cellular depopulation, leading to intractable clinical consequences. However, a far broader population has received stem cells, including patients for whom traditional therapies have proven effective, and outcomes have been conflicting.